WAVE Life Sciences Ltd. WVE
3.78
(0.18)
(4.55%)
as of 25 Sep
- Market cap
- $780.3M
- P/E
- 0.0×
Follow WVE
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(91.62%) | (56.16%) | (53.72%) | (68.31%) | |
| (40.66%) | (41.26%) | (42.11%) | (49.95%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(88.50%) | (38.77%) | (35.41%) | (43.68%) | |
Average Days of Receivables |
33.42 | 10.90 | 0.00 | 4.96 | |
Free Cash Flow per Share |
(1.18) | (1.12) | (0.92) | (0.95) | |
Free Cash Flow |
(198.17) | (188.21) | (185.00) | (193.15) | |
Capital Expenditures |
(0.80) | (0.72) | (0.99) | (1.57) | |
Piotroski F-Score |
3.00 | 2.00 | 2.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(61.53%) | (16.73%) | (17.42%) | (20.29%) | |
Accounts Receivable Turnover |
7.03 | 33.30 | 0.00 | 56.60 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
159.86% | 427.78% | 264.07% | 302.00% | |
Selling, General and Administrative Expense of Revenue |
64.61% | 176.31% | 110.14% | 131.36% | |
Share Based Compensation of Revenue |
19.10% | 58.45% | 40.51% | 51.43% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.62 | 0.92 | 1.00 | 0.95 | |
Depreciation/Fixed assets |
1.07 | 1.20 | 1.27 | 1.34 | |
Capex/Depreciation |
(0.09) | (0.08) | (0.11) | (0.17) | |
Revenue per Share |
0.65 | 0.25 | 0.36 | 0.32 | |
Operating CF per Share |
(1.18) | (1.11) | (0.92) | (0.94) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.02 | |
Net Profit Margin |
(111.64%) | (478.33%) | (255.70%) | (309.73%) |
Columns are period end dates